Targeting the HGF/MET pathway in gastric cancer

Affiliations

Comment

Florian Lordick. Lancet Oncol. 2014 Aug.

. 2014 Aug;15(9):914-6.

doi: 10.1016/S1470-2045(14)70273-6. Epub 2014 Jun 22.

¹ University Cancer Center Leipzig (UCCL), University Clinic Leipzig, D-04103 Leipzig, Germany. Electronic address: direktion.uccl@medizin.uni-leipzig.de.

No abstract available

Comment on

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E. Iveson T, et al. Lancet Oncol. 2014 Aug;15(9):1007-18. doi: 10.1016/S1470-2045(14)70023-3. Epub 2014 Jun 22. Lancet Oncol. 2014. PMID: 24965569 Clinical Trial.